KR20040103968A - Novel biomaterials, their preparation and use - Google Patents

Abstract

The invention is obtainable by a process comprising contacting an anionic polymer component with each cyclodextrin component in an aqueous medium and adding the amphiphilic ammonium-type component to the mixture obtained in step 1, It contains at least an anionic polymer component and an amphiphilic ammonium-type component which are themselves soluble in water, wherein the components are present in the form of precipitates, in particular biocompatible materials, which are present in an amount effective to form the precipitate. And preferably to a corresponding precipitate further comprising said cyclodextrin component. The two types of precipitates may optionally contain one or more additional ingredients. Precipitates are particularly useful as controlled release depot formulations suitable for long, continuous delivery of these additional components. Additional components to be included in the precipitate may be pharmaceutical compounds, pesticides, pesticides, colorants, diagnostics, enzymes, foods, and the like.

Description

New biocompatible materials, preparation methods and uses thereof {NOVEL BIOMATERIALS, THEIR PREPARATION AND USE}

The term “biocompatible material” generally refers to materials having specific characteristics associated with their behavior in the bio-environment. In particular, these substances must disintegrate in their natural environment and must be metabolized after achieving their purpose without leaving any fine amounts at all. In addition, biocompatible materials should not cause adverse reactions, such as inflammatory or toxic reactions in the environment in which they are used. In addition, they should be easy to sterilize and easy to process into the desired product form. In addition, if these materials exhibit mechanical properties suitable for the desired application and they have an acceptable shelf life, this is a great advantage.

The first polymeric biocompatibles made from glycolic and lactic acid have been identified for use in the biomedical industry, beginning with the first biodegradable sutures approved in the 1960s. Subsequently, various products based on lactic acid and glycolic acid and other materials including poly (dioxanone), poly (trimethylene carbonate) copolymers and other poly (ε-caprolactone) homopolymers and copolymers Approved for clinical use as a medical device. In addition to these approved devices, various studies have been conducted on polyanhydrides, polyorthoesters, polyphosphazenes and other biodegradable polymers.

The polymeric biocompatible material may be natural or synthetic. In general, synthetic polymer-materials are particularly specific to natural materials because they can be made to provide a wider range of properties and more predictable lot-to-lot uniformity compared to materials derived from natural sources. Provides the benefits. Synthetic polymers are also more reliable in the source of raw materials and are free of immunogenicity concerns. Thus, there is still a strong need for new synthetic polymeric materials that have important characteristics of biocompatible materials.

The present invention relates to novel polymer-materials, in particular novel biomaterials in the form of certain precipitates, into which other ingredients (especially pharmaceutically active ingredients) which can later be released in their environment in a controlled manner can be incorporated. The invention also relates to a process for the preparation of such precipitates and to pharmaceutical compositions and medical devices based thereon.

It is an object of the present invention to provide such novel solid materials, in particular biocompatible materials having all of the above mentioned characteristics. These substances may incorporate additional ingredients, including particularly pharmaceutically active ingredients, within their matrix, and then in a controlled and reproducible manner, in particular in a delayed manner, especially when the additional ingredients are administered in a conventional manner. It must be able to emit

Surprisingly, it has been found in the present invention that a novel composition comprising at least an anionic polymer component and an amphiphilic ammonium-type component which is itself soluble in water, and which may further comprise a cyclodextrin component, satisfies the above-mentioned object. It was. These compositions are specific precipitates comprising the first two or all three of the above mentioned components, which are characterized by obtainable by a process comprising the following process steps:

1. contacting an anionic polymer component with each cyclodextrin component in an aqueous medium, and

2. Add amphipathic ammonium-type component to the mixture obtained in step 1.

Quaternary onium compounds as cyclodextrins and preservatives (e.g., benzalkonium chloride, benzoxonium chloride, cetylpyridinium chloride or cetyltrimethylammonium bromide, in addition to certain compositions, especially pharmaceutical active ingredients) Compounds, and additionally carriers (optionally also include polymers, including water soluble anionic polymers such as carboxymethyl cellulose, starch derivatives, alginates, pectins, xanthan gum, tracanta rubber or polyacrylic acid-type polymer components). Pharmaceutical compositions) are already known in the art and described in EP-A-0 862 414.

However, these compositions retain the bioavailability enhancing effect that the cyclodextrin compounds have on the pharmacologically active ingredients used in combination with them, while at the same time the preservative efficacy of the preservatives in an amount less than that normally present in the cyclodextrin compounds. Except for the fact that these compositions contain quaternary onium compounds only in amounts necessary to provide a conservative effect, in particular in amounts of up to 0.5% by weight, the compositions of the present invention It is designed to meet a completely different purpose. In order to achieve this object, it is essential that these compositions include alkylene glycol compounds as additional components that provide the aforementioned functionality in addition to their usual functionality as tonicity and / or solubility enhancers. The presence of such alkylene glycol compounds is by no means essential to the present invention.

In addition, the compositions specifically described in EP-A-0 862 414 are aqueous solutions or, in one case, a water-repellent gel having a water content of about 95% by weight, although the compositions described in this reference are also in the form of solid inserts. Although it is mentioned that no specific form of solid material suitable for use as such an insert is mentioned here, in particular, the anionic polymer component and the cyclodextrin component are contacted in an aqueous medium, where necessary No precipitate was described at all by the addition of the amphipathic ammonium-type component in the presence of additional components.

Accordingly, a first object of the present invention is obtained by a method comprising at least an anionic polymer component and an amphiphilic ammonium-type component which is itself soluble in water, and comprising the following process steps, wherein The components are precipitates which are present in an amount effective to form precipitates:

1. contacting the anionic polymer component and the cyclodextrin component in an aqueous medium, and

2. Add amphipathic ammonium-type component to the mixture obtained in step 1.

The precipitate obtained generally comprises all three components mentioned above, namely anionic polymer component, amphiphilic ammonium-type component and cyclodextrin component. However, despite the fact that in certain cases the process is carried out as described above, it has been found that the cyclodextrin component is not substantially incorporated into the precipitate.

This can be easily detected using, for example, HPLC analysis of the obtained precipitates, in particular the above component systems incorporating additional compounds inside their matrix and releasing them again in a reproducible and controlled manner as described above. Does not affect the ability of it at all.

Examples of such cyclodextrin-free precipitates include certain amphiphilic ammonium-type compounds, such as cetyldimethyl (2-hydroxyethyl) ammonium dihydrogen phosphate, benzalkonium chloride or palmitoyl carnitine and gamma-cyclodextrins. There is a precipitate which can be obtained by applying the above-described method for poly (meth) acrylic acid type polymer and hyaluronic acid.

A particularly useful first specific embodiment of the material according to the invention is an anionic polymer component, an amphiphilic ammonium-type component and one or more additional components (eg, pharmaceutically active ingredients, pesticides, pesticides, colorants, diagnostic agents) , An ingredient selected from enzymes, foods, and the like), and can be obtained, for example, by carrying out the abovementioned process steps in the presence of the one or more additional ingredients added in the process of steps 1 and / or 2. Characterized by sediment.

A second particularly useful embodiment of the substance according to the invention is an anionic polymer component, an amphipathic ammonium-type component, a cyclodextrin component, and one or more additional components (eg, pharmaceutically active ingredients, pesticides, pesticides). , A colorant, a diagnostic agent, an enzyme, a component selected from food, etc.), for example, obtained by carrying out the above-mentioned process step in the presence of one or more additional ingredients added in the steps 1 and / or 2. A precipitate characterized by being capable.

The precipitates according to the invention are particularly advantageous in that the anionic polymer component, the cyclodextrin component, and, if present, additional components which are contained in the precipitate and are themselves soluble in water, are dissolved in an aqueous medium as a carrier to form a first Forming a composition; Dissolving the amphiphilic component and blending with the further component, if present, in the precipitate and insoluble in water in a suitable liquid carrier, preferably an aqueous medium, to form a second composition; It can be obtained by contacting the first composition with the second composition to form the corresponding precipitate according to the invention and separating it from the mother liquor.

The anionic polymer component, amphiphilic component and cyclodextrin should be present in an amount effective to form a precipitate. These amounts can vary greatly depending on, for example, the specific compound used to prepare the particular precipitate, the specific composition of the aqueous carrier and the process parameters. Preferably, however, the anionic polymer component is used in an amount of 5 to 30% by weight, in particular 7 to 25% by weight, based on the total amount of the anionic polymer component, the amphipathic component and the cyclodextrin component, while the amphiphilic The components and cyclodextrin components are preferably used in larger amounts, for example the cyclodextrin component is 20 to 70% by weight, in particular 35 to 65 based on the total amount of the anionic polymer component, the amphipathic component and the cyclodextrin component Used in amounts in the weight percent range. Amphiphilic component is preferably 10 to 75% by weight, more specifically 15 to 70% by weight, most specifically 25 to 60% by weight, based on the total amount of anionic polymer component, amphipathic component and cyclodextrin component It is used in the amount of. This is at least about 100 times the amount required when such an amphiphilic ammonium-type component is used to act as a preservative as described in EP-A-0 862 414 (see, eg, Example 2 of this reference). Its contents are considered to be expressly included in the present application).

Their suitable concentration in the aqueous medium or carrier into which the anionic polymer component, amphiphilic component and cyclodextrin are incorporated in contact with each other, of course depends on the solubility of these components in the medium or carrier. On the other hand, these concentrations are rather insignificant due to the low solubility of the precipitates according to the invention in aqueous media, for example they may be rather lower, up to lower values, for example about 0.1% by weight or more. On the other hand, the maximum concentration is generally limited only by the limited solubility of the component in the aqueous medium or carrier. In particular, particularly advantageous concentrations are, for example, in the range from 0.5% to 50% by weight (if possible), preferably from 0.5% to 35% by weight, in particular from 1% to 20% by weight.

For the purposes of the present invention, "aqueous medium" and "aqueous carrier" are liquid media or carriers in which one component, in particular water as the main liquid component, is preferably present in an amount of 90 to 100% by weight of the total aqueous medium or carrier. Should be understood as. The presence of a non-aqueous liquid in the aqueous medium or carrier is not critical as long as it does not interfere with the formation of the precipitate, i.e. as long as it is still sufficiently insoluble in the aqueous medium in which the precipitate is formed. Of course, the non-aqueous liquid must be acceptable in view of the desired use of the precipitate. In a more preferred concept, "aqueous medium" and "aqueous carrier" shall include water as the liquid component and at least one non-toxic non-aqueous liquid should mean a liquid medium or carrier comprising 0 to 5% by weight or less. . Most preferably, suitable grades of water, such as deionized water and / or sterile water, are the only liquid components present in the aqueous medium or carrier, depending on the requirements of the application.

The precipitate according to the invention is very insoluble in the aqueous medium as already mentioned above. Once the anionic polymer component, amphiphilic component, cyclodextrin and, if present, components are contacted in the aqueous medium, the precipitate generally forms fairly quickly, for example within a time of less than 1 second or about 30 minutes. Yields of sediment that can be isolated are typically in the range of 30 to 100% by weight, for example 40 to 90% by weight, of theoretically possible values (ie the sum of the amounts of the educts). The precipitate may of course comprise some amount of the mother liquor liquid component, in particular water, with the amount of water being, for example, in the range of about 2 to 50% by weight, based on the total precipitate. The wet form as obtained immediately after the reaction typically contains a greater amount of water, for example about 40% by weight of water. Depending on the characteristic post-treatment of the precipitate (drying parameters, etc.), the water content generally decreases mainly to values ranging from 2 to 30% by weight, for example from 10 to 20% by weight. It is therefore also possible to produce precipitates according to the invention which contain even lower contents of water.

The detailed internal structure of the precipitate according to the invention is not yet known and does not wish to be bound by any theory, but the components contained within the precipitate by HPLC analysis of the precipitate, in particular anionic polymers, amphiphilic compounds and cyclodextrin compounds, are described above. The formation of precipitates does not appear to react with each other in the chemical sense, and especially covalent bonds do not appear to exist between any of these compounds.

Precipitates according to the invention generally meet the criteria expected from useful biocompatible materials. In particular, the precipitate does not cause an inflammatory or toxic reaction. They can easily be processed into the desired product form, easily sterilized and exhibit an acceptable shelf life. In addition, they exhibit excellent mechanical properties. Thus, for example, if the material is used to support damaged tissue, its mechanical strength is generally kept strong enough until the surrounding tissue has healed.

Certain substances according to the invention, for example hyaluronic acid as anionic polymer component, gamma-dextrin, cetyl-dimethyl- (2-hydroxyethyl) -ammonium dihydrogenphosphate as amphiphilic compound, and optionally elemental iodine The material containing the precipitated precipitate exhibits electrical conductivity.

In addition, the precipitates according to the invention disintegrate rapidly in the natural environment, and are finally metabolized in the body without leaving residues, for example, after fulfilling their purpose. Such biodegradation generally is faster the more hydrophilic the backbone of the anionic polymer component, the more hydrophilic end groups it has, the more hydrolysically reactive groups its backbone, and also the precipitates according to the present invention. The poorer the crystallinity of the polymeric material contained within, and the stronger the porosity, the faster.

A particularly surprising and useful aspect of the present invention is that the precipitates according to the present invention provide a water-insoluble matrix vehicle, in which other components can be incorporated. Without wishing to be bound by any theory, these additional components are included, in part, in molecularly-captured form within the cyclodextrin groups of the precipitate, and / or in part, the micellar-polymeric structure of the precipitate. It seems to be coupled by physical force within). These other components are released in the reproducible and controllable manner, in particular by the precipitate in a delayed manner as compared to when the additional components are administered in free form, so that these additional components incorporated into the precipitate itself The precipitate that follows represents a depot preparation of these additional compounds.

Thus, a preferred embodiment of the precipitate according to the invention comprises at least one further component in addition to the components mentioned above as already mentioned above. These other ingredients are for example selected from pharmaceutically active ingredients, pesticides, pesticides, colorants, diagnostic agents, enzymes and foods.

The anionic polymer component of the precipitate according to the invention comprises a mixture of one or more anionic water soluble polymers.

In the context of these polymers, "water-soluble" means that at least 0.5% and more, in particular 1% and more, of the polymer component can be dissolved in water for the purposes of the present invention. Suitable concentrations generally depend on the viscosity of the resulting solution. Often aqueous solutions of 2-3% by weight of the polymer component are already difficult to handle because they have too high a viscosity. Such solutions can sometimes already be "solid" hydrogels.

The term “anionic polymer” is for the purposes of the present invention at least partially dissociated in an aqueous medium to form anionic molecular groups bonded to the polymer and impart water solubility to the polymer compound, for example carboxylic acid or carboxylic acid salt groups. It means a polymer containing. Suitable anionic polymers include non-toxic water soluble polymers such as hyaluronic acid, carboxymethyl-cellulose, other cellulose derivatives such as methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxy Propylcellulose and hydroxypropylcellulose, poly (meth) acrylic acid type polymers, for example polyacrylic acids such as neutral Carbopol®, or ethyl acrylates, polyacrylamides, natural products, for example gelatin, alginates , Pectin, tragacanta, karaya rubber, xanthan rubber, carrageenan, agar and acacia, starch derivatives such as starch acetate and hydroxypropyl starch carboxymethyl starch, and water-soluble salts of these polymers, Polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl methyl ether or polyethyl Other synthetic products such as lene oxide are also included.

Preferred anionic polymers are hyaluronic acid, carboxymethyl cellulose, carboxymethyl starch, alginic acid, polyacrylic acid-type polymer component, pectin, xanthan gum, tragacanta rubber, water soluble salts of one of the above components and in the polymer or polymer salt It is a mixture of 2 or more types. Especially preferred are hyaluronic acid, carboxymethyl cellulose, xanthan gum, water soluble salts of one of the above components and mixtures of two or more thereof.

The amphipathic ammonium-type component of the precipitate includes one or more amphipathic ammonium-type compounds. Suitable amphiphilic ammonium-type compounds include monomer compounds having one or more, for example two quaternized ammonium groups; And polymers or copolymers of polymer compounds such as monomers having quaternized ammonium groups. The molecular weight of suitable polymeric ammonium-type compounds is for example in the range of 10000 to 1500000, in particular in the range of 35000 to 1000000 (measured by the light scattering method), and the charge density is for example 0.1 to 15, in particular 0.1 to 10 meq / g. For the purposes of the present invention, the term "ammonium-type compound" is understood to include quaternized N-heterocyclic compounds, for example N-substituted pyridinium compounds.

Suitable amphiphilic onium type compounds include cationic surfactants, some of which are commercially available. Particularly preferred amphiphilic ammonium-type compounds are, for example, benzalkonium chloride, benzoxonium-chloride, cetylpyridinium chloride, cetyltrimethylammonium bromide, cocamidopropyl-N, N, N-trimethylglycine, palmitoyl carnitine Sodium-cosylglutamate. Likewise particularly preferred are surfactants and similar forms sold under the trade name Luviquat® (BASF). These include, for example, Ruviquat MONO CP, which is a 30% aqueous solution of cetyldimethyl (2-hydroxyethyl) ammonium dihydrogen phosphate; Luviquat® MONO LS, a 30% solution of lauryl / myristyl-trimethylammonium methylsulfate in water (charge density c. 2.9 meq / g); Or monomeric compounds such as Luviquat Dimer 18 which is a 50% solution of hydroxypropylbisstearyldimethylammonium chloride in a 50/50 mixture of water and ethanol. Suitable surfactants also include polymeric compounds, in particular vinylpyrrolidone and / or vinylcaprolactam and monomers having quaternized ammonium groups, for example trialkylammonium (meth) acrylates or N-alkylvinylimidazoli Copolymers with nium compounds. Suitable polymeric surfactants have, for example, molecular weights of 25000 to 1000000 and greater (measured by light scattering methods) and charge densities in the range of 0.3 to 10 meq / g. Examples thereof include c. In an aqueous solution of 19-21% solids content c. Luviquat is a copolymer of 67% by weight vinylpyrrolidone and 33% by weight dimethylethylammonium-methacrylate ethylsulfate having a molecular weight of 1000000 (measured by the light scattering method) and a charge density of 0.8 meq / g. ®) Q 11PN; In water / ethanol solution of 19-21% solids c. Of 50 wt% vinylcaprolactam, 40 wt% vinylpyrrolidone and 10 wt% N-methylvinylimidazolinium methyl sulfate having a molecular weight of 700000 (measured by the light scattering method) and a charge density of 0.5 meq / g Copolymer Luviquat Hold; And Ruviquat® FC 370, Luviquat, a copolymer of vinylpyrrolidone (VP) and N-methylvinylimidazole (QVI) in an aqueous solution having a composition as detailed in the table below ®) HM 552, Luviquat® FC 905, Luviquat® Care includes:

product name Composition [% by weight] Negative ion Solid content [%] Molecular weight ^A) Charge density [meq / g] VP QVI Luviquat® FC 370 70 30 Cl ^- 38-42 c. 100000 2.0 Luviquat® FC 550 50 50 Cl ^- 38-42 c. 80000 3.3 Luviquat® HM 552 55 45 Cl ^- 19-21 c. 400000 3.0 Luviquat® FC 905 5 95 Cl ^- 38-42 c. 40000 6.1 Luviquat® Care 80 20 H ₃ CSO ₄ ^- 6-7 c. 1000000 1.09 A) measured by light scattering method

Commercially available suitable surfactants may also contain small amounts of additives, for example preservatives such as alkylparaben compounds, and inert organic solvents, which are determined by a skilled practitioner according to the requirements in the particular field of precipitation use. It can be chosen easily.

Another specific embodiment of a suitable amphiphilic ammonium type compound is the corresponding cationic phospholipid, in particular lysophosphatidyl-choline compound, for example phosphatidyl choline compounds such as egg yolk-phosphatidyl choline, sphingomyelin, corresponding sphing High derivatives and mixtures thereof. Phospholipids such as these have the advantage that they are derived from natural products and are therefore particularly compatible with tissues, while on the other hand they have the hardness and hardness (precipitation) of sediments comprising this type of amphiphilic component. consistency has been found to be less favorable than the precipitate according to the invention based on other amphiphilic ammonium-type compounds. Phospholipids may also be used with other amphiphilic ammonium-type compounds, in particular with the amphiphilic ammonium compounds mentioned above.

Benzalkonium-chloride, benzoxonium-chloride, cetylpyridinium chloride cetyltrimethyl-ammonium bromide, cetylpyridinium chloride cetyltrimethylammonium bromide; Cetyldimethyl (2-hydroxyethyl) ammonium dihydrogen phosphate (Luviquat® MONO CP), cochamidopropyl-N, N, N-trimethylglycine, acyl carnitine derivatives, such as in US Pat. No. 4,194,006 or 5,731,360 Those described, in particular palmitoyl carnitine; Amphiphilic ammonium type compounds selected from the group consisting of sodium cosyl glutamate and mixtures of one or more of the members of the group are particularly preferably chosen for the precipitates of the invention.

The cyclodextrin component of the precipitate according to the present invention may comprise one or more cyclodextrin compounds. Cyclodextrin compounds referred to in the present invention are alpha-, beta- or gamma-cyclodextrins themselves, derivatives thereof, such as partially etherified derivatives such as hydroxyalkyl ether derivatives, or mixtures thereof. It should be noted that the randomly selected cyclodextrin compound does not automatically form an inclusion complex which may be desirable to be incorporated into the precipitate of the present invention with any other compound selected randomly. Thus, in such cases it is desirable to use cyclodextrin compounds that meet the cavity requirements of other components or components to be incorporated into the precipitate. Their correlation is known to those skilled in the art.

Suitably substituted alpha-, beta- or gamma-cyclodextrins are, for example, alkylated, hydroxyalkylated, carboxyalkylated or alkyloxycarbonyl-alkylated derivatives. Other representative examples are mono- or diglycosyl-alpha-, -beta- or -gamma-cyclodextrins, mono- or dimaltosyl-alpha-, -beta- or -gamma-cyclodextrins or panosyl-cyclodextrins. Hydrocarbon derivatives of such cyclodextrins.

Preferred precipitates according to the invention include in particular those in which the cyclodextrin component is selected from alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin and mixtures thereof.

If necessary, the precipitates according to the invention can also be used in addition to the components mentioned, in small amounts, for example from 0.0001 to 5% by weight, for example from 0.1 to 3% by weight of effective additives such as stabilizers or preservatives, and It may also contain compatible modifiers such as plasticizers or flexibiizers.

Precipitates according to the invention are continuously or simultaneously in an aqueous medium in an amount effective to form the precipitate, for example, an anionic polymer component, an amphiphilic ammonium-type component, a cyclodextrin component, and another component to be incorporated into the precipitate. It may be prepared by a method of contacting each other, wherein at least the anionic polymer component, the amphiphilic component and the cyclodextrin component are present in dissolved form when contacted, and the amount of the components is selected such that a precipitate is formed.

In the process described above, the formation of a precipitate immediately reduces the viscosity of the reaction mixture. The precipitate can then be separated off as a wet polymer, for example by filtration or centrifugation.

Optionally, the dry precipitate can be obtained after sufficient and careful drying. Drying, for example, washes the wet precipitate optionally, preferably once or several times with water, and then immerses it in a cooled volatile organic solvent such as acetone, preferably having a temperature of less than 12 ° C. For a period of time, for example, for a few minutes to about 1 hour, it can be advantageously carried out by keeping it in contact with the solvent, then separating it and optionally removing residual solvent at elevated temperatures and / or under vacuum.

Dry precipitates are converted into elastic, flexible rubber-like plastics upon contact with water, which does not show significant swelling in water upon rewetting. The rewet matrix appears to be physically stable when stored in water at ambient temperature for at least 6 months. No bacterial or fungal infection was observed even when the rewet matrix was stored for 6 months in a sealed polyethylene bag containing deionized water.

If desired, the precipitate can be readily converted into any desired form using conventional methods such as, for example, pressing or rolling. Likewise, fibers, sheets or threads can be formed from the precipitates according to the invention.

In a preferred embodiment of the process for preparing the described precipitates, the anionic polymer component, the cyclodextrin component, and additional components soluble in the water to be incorporated into the precipitate are dissolved in an aqueous medium to form a first composition; Amphiphilic ammonium-type components, and additional components insoluble in the water to be incorporated into the precipitate, are blended with a suitable liquid carrier, preferably an aqueous medium, to form a second composition; The first and second compositions are blended to form a precipitate.

This embodiment of the process of the invention can be advantageously used, for example, to form a coating of the precipitate according to the invention on a solid carrier. In this case, the method includes coating the carrier with the first composition and subsequently treating the treated carrier with the second composition to form a coating of the precipitate thereon. Administration of the first and / or second composition onto the carrier can be performed, for example, by spraying or by another suitable method.

Precipitates according to the invention are particularly useful in biomedical applications with regard to their biocompatible-characteristics. They can be used on their own, i.e. without any additional ingredients, for example to produce biodegradable surface coatings, surgical wound covers, dressings or yarns.

However, a particularly useful embodiment of the present invention is a precipitate comprising one or more additional ingredients comprising a pharmaceutically active ingredient. Pharmaceutically active ingredients include, for example, steroids, prostanoids, nitric oxide prodrugs, antihistamines, antibiotics, cytostatic agents, antiviral agents, peptide hormones, local anesthetics, antiglaucoma drugs, anti-inflammatory agents, antihypertensive agents, antiangiogenic agents And suitable mixtures thereof. The amount of pharmaceutically active ingredient can vary within wide limits depending upon the particular indication and requirements. Suitable amounts of pharmaceutically active ingredient are, for example, in the range of 1 to 20% by weight, specifically 3 to 15% by weight, more specifically 5 to 10% by weight, based on the total precipitate.

These pharmaceutically effective precipitates are particularly useful for making medical devices such as medical implants or inserts, or medical surface coatings, surgical wound covers or seals.

However, particularly preferred is the use of such precipitates in the manufacture of medicaments. The invention therefore also relates to a pharmaceutical composition comprising a precipitate according to the invention comprising a pharmaceutically active ingredient.

In particular, the generally delayed release of the pharmaceutically active ingredient from the precipitate as compared to the case where the pharmaceutically active ingredient is administered in free form, for example, may lead to the precipitation of the present invention in the preparation of depot formulations of all types of pharmaceutically active ingredient. Make it as useful as possible

The pharmaceutical compositions may, of course, be administered in any suitable manner, but such compositions may be administered continuously or simultaneously with one or more compositions, each of which comprises one or more of the components of the precipitate to be administered to form a precipitate at the site of administration. It can also be administered. By way of example, such partial compositions may be injected into a living body, for example subcutaneously or intramuscularly, to form, for example, a subcutaneous or intramuscular depot of the desired pharmaceutically active ingredient in the desired position. Likewise, wounds, skin or other solid organic surfaces may be formed, for example, by continuously spraying such partial compositions at a desired location to form a coating that can deliver the desired pharmaceutically active ingredient at that location for extended periods of time. Pharmaceutical compositions may also be administered to the stomach.

Thus, a further object of the present invention comprises two or more partial compositions, each composition comprising one or more components which are not all of the components of the pharmaceutical composition so that the precipitates are brought into contact when they are in contact with each other. A pharmaceutical composition according to the present invention, which is present in a composition for continuous or simultaneous administration in an amount effective to form a compound, wherein the portions of the composition are administered simultaneously or preferably continuously to a subject, thereby forming the composition at the location where it was administered. Is a kit for administering.

Specific forms of the kits described include a first composition comprising an anionic polymer component, a cyclodextrin component, and additional components dissolved in an aqueous medium that are soluble in the water to be incorporated into the precipitate; And a second composition comprising an amphiphilic ammonium component and a component insoluble in the water to be incorporated into the precipitate, while blended with a suitable liquid carrier, preferably an aqueous medium.

Specific embodiments of such kits include corresponding kits for subcutaneous or intramuscular administration of the pharmaceutical composition, and for administering the pharmaceutical composition, for example by spraying on wounds, skin, or other solid organic surfaces. do.

A further subject of the invention is a method of administering a pharmaceutically active compound to a subject in need thereof, comprising administering a pharmaceutical composition according to claims 15 or 16 comprising said pharmaceutically active compound. to be.

Another subject matter of the present invention includes the formation of a pharmaceutical composition at the site of administration at the same or preferably by successive administration of two or more partial compositions, each comprising one or more of the components of the pharmaceutical composition. A method of administering a pharmaceutical composition as described above to a subject, wherein the components to form a precipitate are present in the partial composition in an amount effective to form a precipitate when in contact with each other.

Specific embodiments of this method include a first composition comprising an anionic polymer component, a cyclodextrin component, and a further component soluble in water incorporated in the precipitate, dissolved in an aqueous medium; And simultaneous or preferably continuous administration of the amphiphilic ammonium component and the second composition comprising a component insoluble in water incorporated into the precipitate, while blended with a suitable liquid carrier, preferably an aqueous medium.

The partial composition can be administered, for example, by subcutaneous or intramuscular injection to the subject, or preferably by spraying onto the wound, skin or other solid surface of the subject.

The following examples illustrate the invention in more detail.

Example 1 : Preparation of hyaluronic acid / surfactant / gamma-cyclodextrin biocompatible material

This example describes the basic precipitate according to the invention and its preparation method.

50 g of gamma-cyclodextrin (gCD) was dissolved in 950 g of deionized water at 25 ° C. to form a slightly cloudy solution. 10 g of sodium-hyaluronate was added to the stirred gCD solution and the mixture was stirred at 25 ° C. for 60 minutes to obtain a clear or slightly milky thick solution containing no solid particles. To this aqueous solution was added 65 ml of Luviquat Mono CP solution containing 30% (19.5 g) cetyl-dimethyl- (2-hydroxy-ethyl) -ammonium dihydrogen-phosphate at 150 rpm. It was added with stirring (commercial Rubikuat mono CP solution was purchased from BASF). The solution turned to a white suspension, and a white rubber-like polymer precipitate formed within about 20 minutes after adding the surfactant. The reaction mixture was stirred for an additional 10 minutes at 150 r.p.m. and then left at ambient temperature to settle the precipitate. The product was isolated by filtration and washed three times with 500 ml of deionized water. The washed wet product was a white rubber-like viscoelastic polymer. After drying at ambient temperature under vacuum, 60 g of a white amorphous solid were obtained (yield: 75%).

Three different batches were prepared according to the techniques described above and analyzed by HPLC method. Table 1 lists the analysis results of the insoluble polymer matrix formed after redissolution in methanol.

HPLC analysis of the composition of the precipitate prepared according to Example 1 Batch number Composition by HPLC (%) yield(%) Na-hyaluronate g-CD Luviquat® Mono CP 20/51/1 12.4 56.9 18.0 75 20/51/2 12.7 52.0 26.3 74 20/51/3 12.8 52.0 26.0 71

From the data, the reproducibility of the preparation method is considered acceptable. The product prepared according to Example 1 has a similar composition as shown by HPLC analysis. The mother liquor of the reaction mixture was analyzed by HPLC and found to contain both gCD and surfactant, but no hyaluronic acid sodium salt.

Knowing the actual moisture content of these dried biocompatible materials is also analytically important. The moisture content of the samples was determined by both loss on drying and Karl-Fisher methods. The water content of three consecutive batches is shown in Table 2 below:

Moisture Content and Loss on Drying Value of Biocompatible Materials According to Example 1 Sample Moisture content by Karl Fischer (%) Loss on Drying (%) 20/51/1 14.3 15.9 20/51/2 14.8 15.5 20/51/3 14.0 16.0

Differential scanning calorimetry shows water loss in different temperature ranges. This suggests that the water content of the samples according to the invention is composed from the combined water fractions in different ways.

Example 2 : Physical and chemical characterization of the biocompatible material according to Example 1

Chemical composition

Analysis of the composition of the hyaluronic acid / surfactant / gamma-cyclodextrin biocompatible material was performed using HPLC and capillary electrophoresis techniques. In addition to the composition of the matrix, these techniques provide information on the chemical intactness of all three components present in the matrix, suggesting that chemical conversion of the components does not occur with the formation of the biocompatible material. Near-infrared (NIR) and NMR spectroscopy provide further evidence of the fact that no new chemical body is formed by the interaction of the three components to obtain a water-insoluble matrix.

Solid State Characteristics of Hyaluronic Acid / gCD / Surfactant Matrix

The white stone hardness solid matrix shows an X-ray amorphous. The exact melting point cannot be determined using conventional melting point apparatus. Upon heating, the solid material does not show any phase transition up to 210 ° C, but above this temperature the polymer matrix turns brown and decomposes by heat.

Thermal analysis by differential scanning calorimetry in an inert gas atmosphere further supports the above observations. The biocompatible material according to the invention in nitrogen atmosphere does not exhibit an accurate melt endothermic peak. However, they are characterized by a very wide endothermic heat flow that occurs between 40-188 ° C. This process has a maximum at approximately 100 ° C., so this seems to be related to the loss of bound water. At higher temperatures, this process is probably duplicated by glass transition. The endothermic heat flow begins at 188 ° C. and continues up to 215 ° C. by rapid endothermic heat flow. This is presumed to be a result of solid state chemical reactions between the components, or more possibly pyrolysis of the polymer matrix.

Example 3 : Preparation of Luviquat Mono CP surfactant / hyaluronic acid / alpha-cyclodextrin biomaterial

16 g of alpha-cyclodextrin (aCD) was dissolved in 150 g of deionized water at 25 ° C. To the stirred aCD solution was added 2.0 g of sodium-hyaluronate and the mixture was stirred at 25 ° C. for 45 minutes to give a clear and thick solution. To this solution was added 6.6 ml of Luviquat Mono CP (30% aqueous solution purchased from BASF) with stirring. The solution turned to a white suspension and a white rubber-like polymer precipitate appeared within 30 minutes after the addition of the surfactant. The reaction mixture was stirred for 30 minutes, then left at room temperature to settle the precipitate. The precipitate was isolated by filtration and washed five times with 30 ml of deionized water. After drying in vacuo at ambient temperature, 12 g of a white, glassy solid were obtained (yield: 60%).

Example 4 : Preparation of Luviquat Mono CP surfactant / hyaluronic acid / beta-cyclodextrin biocompatible material

18 g of beta-cyclodextrin (bCD) was dissolved in 800 grams of DI water at 37 ° C. To the stirred bCD solution was added 2.0 g of sodium-hyaluronate and the mixture was stirred at 37 ° C. for 30 minutes to give a weak milky thick solution containing no solid particles therein. To this solution was added 6.5 ml of Luviquat Mono CP (30% aqueous solution purchased from BASF) with stirring. The reaction mixture was cooled from 37 ° C. to 25 ° C. to change the solution to a white suspension and a white amorphous polymer precipitate appeared within 45 minutes after the addition of surfactant was complete. The reaction mixture is stirred at 20 ° C. for 30 minutes and then left in the refrigerator. The precipitate was isolated by filtration and washed five times with 15 ml of deionized water. 7.0 g of a white glassy solid was obtained after drying in vacuo at ambient temperature (yield: 31.8%).

Substitution of hyaluronic acid by other anionic polymers

The basic phenomenon of formation of the water-insoluble biocompatible material observed for hyaluronic acid quaternary-ammonium-type surfactants / cyclodextrins was also found to be manifested by several other water soluble anionic polymers of different chemical structures. Anionic polymers react with cationic amphiphilic molecules (e.g. surfactants) through ionic interactions, and cyclodextrins react with nonpolar-nonpolar interactions on the lipophilic tails of the surfactants. It is assumed to bind to the salt. This is the reason why even highly soluble cyclodextrin components of the polymer matrix cannot be removed by excessive washing with water.

The following conventional water soluble ionic polymers were included:

Polysaccharides:

Sodium alginate

Carboxymethyl-cellulose

Carboxymethyl starch

Xanthan Rubber

-Pectin

-Tragacanta Rubber

Polyacrylates:

Carbopol 980 NF

Pioneer NP 37N

Each of the three anionic polymers has been found to provide positive reactions with quaternary ammonium-type surfactants and cyclodextrins, that is, they all form water-insoluble precipitates, as detailed in the Examples below. It was.

Example 5 Preparation of carboxymethyl-cellulose (CMC) / cetyl-trimethyl-ammonium-bromide (CTAB) / g-cyclodextrin (gCD) biomaterial

Two separate aqueous solutions were prepared at room temperature and reacted as follows:

Solution 1: 100 mL of 1% carboxymethyl-cellulose was prepared and 5 g of crystalline gCD was added little by little while stirring at 25 ° C.

Solution 2: 100 ml of 5% Cetyl-trimethyl-ammonium-bromide aqueous solution

Process: Solution 2 was added to Solution 1 with gentle stirring at 25 ° C. (approx. 30 r.p.m.). Feeding solution 2 immediately formed a white precipitate. After the two solutions were thoroughly mixed at about 30 r.p.m for 10 minutes, the insoluble matrix formed was filtered on a glass filter by vacuum. The wet precipitate was washed five times with 100 ml of deionized water. Water washing has been found to improve the viscosity, physical / mechanical properties (elasticity, hardness) of the formed matrix. The wet washed product was spread out into a layer about 3-5 mm thick and allowed to dry in air for 12 hours.

Yield: 8.2 g (74%) of white amorphous polymer was obtained.

Composition of the Polymeric Material Prepared According to Example 4 Sample Analysis of the components by HPLC (%) * CMC g-CD CTAB Matrix of Example 5 About 12 Approximately 52 About 30

Example 6 Preparation of xanthan rubber / cetyl-trimethyl-ammonium-bromide (CTAB) / g-cyclodextrin (g-CD) biomaterial

Two separate aqueous solutions were prepared at room temperature and reacted as follows:

Solution 1: 1 g of xanthan gum was dissolved in 100 mL of deionized water, and then 5 g of crystalline gCD was added with stirring at 25 ° C. The resulting solution was a slightly cloudy and thick solution.

Solution 2: 5 g of cetyl-trimethyl-ammonium-bromide was dissolved in 100 mL of deionized water to give a clear and clear solution.

Process: Solution 2 was added to Solution 1 with gentle stirring at 25 ° C. (approx. 30 r.p.m.). Feeding solution 2 gave a colorless precipitate immediately. After the two solutions were thoroughly mixed at about 30 r.p.m. for 10 minutes, the insoluble jelly-like matrix formed was filtered. The wet slightly milky colorless polymer object was washed five times with 100 ml of deionized water. The wet product was spread out in a layer about 3-5 mm thick and allowed to dry in air for 12 hours.

Yield: 9.1 g (81%) of white glassy polymer was obtained, the composition of which is shown in Table 4.

HPLC analysis of the composition of the polymer matrix prepared according to Example 6 Sample Analysis of the components by HPLC (%) * Xanthan rubber g-CD CTAB Matrix according to Example 6 About 10 About 50 Approximately 35

Example 7 : Preparation of xanthan rubber / benzalkonium chloride (BAC) / g-cyclodextrin (gCD) biocompatible material

Two separate aqueous solutions were prepared at room temperature and reacted as follows:

Solution 1: 1 g of xanthan gum was dissolved in 100 mL of deionized water, and then 5 g of crystalline gCD was added with stirring at 25 ° C. The resulting solution was a slightly cloudy and thick but agitable solution.

Solution 2: 10 mL of 50% (w / v) benzalkonium chloride was used.

Process: Solution 2 was added to Solution 1 with gentle stirring at 25 ° C. (about 45-50 r.p.m.). Immediate precipitation formation was observed upon addition of benzalkonium chloride solution. After the two solutions were fully integrated and thoroughly mixed, a rich insoluble colorless polymer object was formed. Insoluble jelly-like matrix was obtained by filtration. The wet polymer object was washed five times with 150 mL of deionized water, spread into a layer of about 3-5 mm thick and then allowed to dry in air.

Yield: 10.2 g (92%) of a colorless polymer was obtained.

Example 8 : Selection of Quaternary Ammonium Type Surfactant Components to Produce Biocompatible Materials

Commercially available surfactants of the following different molecular structures were selected as suitable materials for the preparation of the biocompatible materials according to the invention:

Cetyl-pyridinium-chloride, CPC (Merck)

Cetyl-trimethyl-ammonium-bromide, CTAB (Merck)

Benzalkonium Chloride, BAC (Eu. Pharm.Grade, Norvatis)

Benzoxonium chloride, BOC (Eu. Pharm.Grade, Norvatis)

Cochamidopropyl-N, N, N-trimethyl-glycine (Goldschmidt)

Luviquat ™ (BASF) product group of surfactants: Luviquat Hold, Luviquat FC 905, Rubiquat FC 550, Rubiquat FC 370, Rubiquat Care ( Luviquat Care), Rubiku Art HM 552, Rubiku Art PQ 11 PN, Rubiku Art Mono CP, Rubiku Art Mono LS.

Example 9 : Amino acids and amine derivatives having quaternary ammonium moieties for the preparation of biocompatible materials

Substitution of quaternary ammonium type surfactants with naturally occurring and more tissue-friendly analog compounds could improve the practical utility of these polymer matrices. Systematic screening led to the recognition that structurally similar materials having no longer alkyl-chains and having quaternary ammonium sites are not suitable for forming the water-insoluble matrix according to the present invention (see Table 5).

Reaction of hyaluronic acid, quaternary ammonium type material and gCD Surfactant substituents Reaction with hyaluronic acid / gCD opinion Choline chloride No precipitation The reaction mixture is kept clear L-carnitine No precipitation The reaction mixture is kept clear N-Guanidinomethyl L-Arginine No precipitation The reaction mixture is kept clear N, N, N-trimethyl-L-lysine No precipitation The reaction mixture is kept clear

From the above data, it can be seen that the presence of lipophilic moieties on the quaternary ammonium-type compound is an important prerequisite for the formation of precipitates and therefore the material must be of amphipathic nature.

Example 10 Selection of non-surfactant quaternary ammonium type components for the formation of biocompatible materials

In addition to the matrix forming cationic surfactants described above, several naturally occurring tissue compatible phospholipids have also been identified that can be used to prepare biocompatible materials according to the present invention. However, the hardness and hardness of such biocompatible materials are less desirable than the hardness and viscosity of biocompatible materials made with surfactants.

The following materials were found to form a polymer matrix with anionic polymers:

-Sphingomyelin

-Sphingosine

Lysophosphatidyl-choline

Example 11 : Incorporation of water-soluble ketotifen hydrogen fumarate into the biocompatible material according to Example 1

Drug-loaded polymer matrices can be prepared predominantly in one pot reactions. If the active drug incorporated is a water soluble drug, it can be dissolved together with the cyclodextrin and the water soluble anionic polymer component. Water-insoluble actives can be incorporated in a similar manner except dissolving them with surfactants or phospholipids, as described in detail below:

5.0 g gCD (3.9 mMol) was dissolved in 89.7 g deionized water. 1.6 g of ketotifen-hydrogenfumarate (3.9 mMol) was added to the stirred gCD solution with continuous stirring. Thereafter, 1.0 g of Na-hyaluronate was added to a slightly hazy ketotifen-g-cyclodextrin solution and the mixture was stirred at 25 ° C. for 60 minutes at 600 r.p.m. The reaction mixture became a thick and viscous solution within about 15 minutes. To this thick solution was added dropwise a 30 ml solution of 3.3 ml Luviquat Mono CP corresponding to 1.0 g of surfactant. The clear reaction mixture was immediately converted to a milky suspension, from which a semisolid "object" precipitate was formed. Stirring at room temperature for another 30 minutes yields a white rubber-like polymer matrix. Insoluble material was isolated by simple filtration. The wet product was washed five times with 5 ml of cold water and dried to constant weight at ambient temperature under vacuum. Yield: 6.2 g (70% yield) of a white glassy solid with a ketotifen content of 8.0%.

Example 12 : Pharmaceutical Performance of HA / gCD / Mono CP Matrix According to Example 1

Two consecutive batches of the polymer matrix were prepared on a laboratory scale and loaded with ketotifen hydrogenfumarate, a water soluble investigational drug selected according to the method described in Example 11. In vitro release profiles of ketotifen depot formulations were performed as follows:

1 g of dry polymer matrix loaded with ketotifen-hydrogenfumarate according to Example 11 was stirred at 37 ° C. in 50 ml of deionized water at 600 r.p.m. The released amount of ketotifen-hydrogenfumarate was measured by HPLC. The results of the in vitro release test for the two parallel batches are shown in Table 6.

Release of ketotifen-hydrogenfumarate from two consecutive batches of HA / gCD / mono CP polymer matrix according to Example 1 in deionized water at 37 ° C. Time (min) Ketotifen-hydrogenfumarate released (mg / ml) HA / gCD / mono CP / drug (batch 1) HA / gCD / mono CP / drug (batch 2) 5 0.19 0.20 10 0.29 0.30 20 0.37 0.42 30 0.45 0.50 40 0.50 0.55 50 0.52 0.56 60 0.50 0.62 80 0.58 0.63 100 0.57 0.66 120 0.62 0.64

The data above indicate that batch versus batch reproducibility of the process of producing the drug-loaded matrix provides a biocompatible material that is acceptable and has reproducible pharmaceutical performance. 40% of the total dose of ketotifen was released within 2 hours from the HA / gCD / mono CP matrix according to Example 1 in a stirred aqueous system, while the release of ketotifen as it was non-formulated was the same It appeared to be much faster under conditions (the same system without any agitation, ie allowing only to stand in water, can release 40% of loaded ketotifen hydrogenfumarate within only about 4-5 days) .

Example 13 : Effect of Changes in Matrix Composition on Release of Water-Soluble Drugs

Changes in the composition of the water-insoluble matrix prepared according to the invention were found to affect the release profile of the entrapped drug. A matrix with an 8% ketotifen loading was prepared as described in Example 11. One contained 1% hyaluronic acid while the other contained 0.5% hyaluronic acid. Reducing the hyaluronic acid content in the reaction solution by 50% was found to provide this drug-loaded biomaterial with much less delayed ketotifen release (see Table 7). In vitro dissolution testing was performed as described in Example 12.

In vitro release of ketotifen-hydrogenfumarate from different HA / gCD / mono CP polymer matrices into deionized water at 37 ° C. Time (min) Ketotifen-hydrogenfumarate released (mg / ml) Matrix manufactured with 1.0% hyaluronan Matrix made with 0.5% hyaluronan 5 0.20 0.49 10 0.31 0.60 20 0.37 0.69 30 0.44 0.76 40 0.50 0.78 50 0.55 0.78 60 0.55 0.79 80 0.60 0.88 100 0.60 0.90 120 0.62 0.95

Based on the above data, it can be mentioned that the in vitro release of water soluble drugs from the biodegradable matrix according to the invention can be adjusted by varying the amount of polymer component in the biocompatible material.

Example 14 Preparation of carboxymethyl-cellulose / cetyl-trimethyl-ammonium-bromide / g-cyclodextrin biomaterial

Two separate aqueous solutions were prepared at room temperature.

Solution 1: 100 ml of 1% carboxymethyl-cellulose and 5% g-cyclodextrin aqueous solution

Solution 2: 100 ml of 5% Cetyl-trimethyl-ammonium-bromide aqueous solution

fair:

Solution 2 was added to Solution 1 with gentle stirring at 25 ° C. (about 30 r.p.m.). Feeding solution 2 gave an immediate white precipitate. After mixing the two solutions at about 30 r.p.m. for 10 minutes, the insoluble matrix formed was filtered by vacuum and washed five times with 100 ml of deionized water. Water washing was found to improve the viscosity, physical / chemical properties (elasticity, hardness) of the formed matrix. Further washing did not reduce the amount of insoluble material. 8.1 g of a white amorphous solid (yield: 74%) were obtained.

Example 15 Preparation of Carbopol® 980 NF / cetyltrimethylammonium bromide / gamma-cyclodextrin biomaterial

Solution 1: 5 grams of gCD and 1 gram of Carbopol® were dissolved in 90 mL of deionized water.

Solution 2: 3.3 ml of 30% Luviquat Mono CP solution

Process: Solution 2 was added to stirred Solution 1 at 25 ° C. Mixing the two solutions formed a white precipitate. After about 30 minutes of reaction time no object formation was observed, only a floppy white precipitate was obtained. The reaction mixture was placed in a refrigerator (5 ° C.) for 12 hours to induce the formation of a thick gel. The gel was diluted with 4000 mL deionized water to settle the white insoluble polymer matrix. The precipitate was filtered off and washed five times with 100 ml of water. The resulting matrix was 5.3 g of a white, stable elastomer (yield: 75%).

Example 16 : Surface coating with polymer / cyclodextrin / surfactant formulation

Surprisingly, among the anionic polymers tested, Carbopol and Carboxymethyl-Cellulose are products that can be used in diluted form to cover various surfaces by water-insoluble coatings after reaction with quaternary ammonium type surfactants and cyclodextrins. It was confirmed to provide.

Metals, glasses and polymers and skin surfaces were treated by applying the reaction mixtures according to the invention in turn (aqueous polymer and cyclodextrin solution followed by cationic surfactant solution). After drying, a flexible but continuous polymer layer was formed on the treated surface. The coating cannot be removed by washing even with an excessive amount of water. Only strong physical interference, excessive heat or bio-erosion can remove or destroy these coatings. The stainless steel surface was coated with the Carbopol / Cetyl-trimethyl-ammonium-bromide / g-cyclodextrin composition prepared according to Example 15. The coating formed on the steel was found to be resistant to excessive water washing. However, after 10 washes with 100 ml of 9% NaCl aqueous solution, the physical corrosion of these coatings began. The degree of physical degradation was found to increase as the ionic strength of the surrounding solution increased.

Example 17 Surface coating with hydrocortisone-loaded polymer / cyclodextrin / surfactant formulation

The stainless steel surface (area >> 15 cm 2) was subsequently treated with the following two solutions prepared according to the invention:

Solution 1: 5 g of g-cyclodextrin and 1 gram of Carbopol were dissolved in 90 mL of deionized water.

Solution 2: 3.3 ml of 30% Luviquat Mono CP solution containing about 1 g of cetyl-dimethyl- (2-hydroxyethyl) -ammonium hydrogenphosphate. 0.1 g of hydrocortisone was dissolved in this solution.

The metal surface was first treated with solution 1 and then with solution 2. Within 5 minutes a white precipitate covered the steel surface. The surface was allowed to dry in air. In vitro release of hydrocortisone captured from the metal surface was tested in water and in 0.9% NaCl solution at 37 ° C. After stirring for 2 hours in water, only about 20 μg of hydrocortisone was released, while about 90 μg of steroid was released during the same time in 0.9% NaCl solution.

Example 18 : Characterization of physical corrosion of polymer / surfactant / cyclodextrin matrices

Since the principle of formation of polymer / cyclodextrin / surfactant insoluble matrices is a combined effect of electrostatic and nonpolar-nonpolar interactions, the presence of salts (NaCl, NaBr, KCl, etc.) according to published data indicates It was expected to be able to initiate and accelerate. Indeed, it has been found that in the presence of salts such as NaCl, matrices prepared using hyaluronic acid, in particular, are physically degraded in a cation concentration-dependent manner.

Under iso-osmotic conditions, ie in 0.9% NaCl solution, the hyaluronic acid / surfactant / gCD insoluble material is converted to water soluble within 8-10 days of storage at room temperature.

Complete dissolution of the matrix under high osmotic conditions (eg in 5 or 10% NaCl) occurs within 2 days.

Therefore, biocompatible materials made from Carbopol or carboxymethyl-cellulose / surfactant / cyclodextrin remain physically much more stable in 5% NaCl solution. These biocompatible materials show no disintegration after 20 days of storage in 0.9% NaCl. Thus, for depot formulations that last longer, carbopol- and carboxymethyl-cellulose based biomaterials may be preferably used.

Example 19 Release of Curcumin from Colorant-Loaded Biocompatible Materials According to the Invention

Colorant Loaded biomaterials were prepared by dissolving curcumin colorant in the applied surfactant. The colorant loaded biomaterial prepared according to Example 11 contained 4.5 wt% curcumin. The yellow colored matrix was cut into two equally sized portions and immersed in deionized water and 0.9% NaCl solution. The in vitro release profile of the colorant from the solid matrix was determined as follows:

10 g of the polymer matrix loaded with curcumin according to Example 11 was stirred at 50 r.p.m. in 50 ml deionized water at 37 ° C. The amount of curcumin released was measured by spectrophotometry. The results of the in vitro release test are listed in Table 8.

Release of curcumin from hyaluronic acid / benzalkonium-chloride / gCD biocompatible in water and in 0.9% NaCl at 25 ° C. Time (min) Curcumin released (%) * In the water In 0.9% NaCl 5 1.5 8.5 10 2.9 13.3 20 3.2 13.4 30 3.2 15.3 40 3.5 18.0 50 4.1 18.6 60 4.5 26.7 80 4.8 27.3 100 5.5 27.6 120 6.2 28.5 When the total amount of curcumin is released, this means 100%.

The above data suggest that the degree of release of the entrapped material from the biodegradable matrix according to the present invention is determined by the actual ionic strength of the dissolution / ambient medium. When such a biocompatible material loaded with a pharmaceutically active material is implanted, the release of the captured active material will be determined primarily by the ion concentration of surrounding tissues and, to a lesser extent, by the enzyme present.

Example 20 Release of Curcumin from Colorant-Loaded Biocompatible Materials According to the Invention

Steroid-loaded biomaterials were prepared by dissolving testosterone in a benzalkonium-chloride surfactant. The drug-loaded biocompatible material prepared according to Example 11 contained 9.0 weight percent testosterone. The testosterone loaded matrix was cut into two equally sized portions and immersed in deionized water and 0.9% NaCl solution. The in vitro release profile of steroids from the solid matrix was measured as described below:

10 g of the polymer matrix loaded with testosterone according to Example 11 were stirred in 100 ml of deionized water and at 300 r.p.m. in 100 ml of 0.9%, 3.0% and 5.0% NaCl solution at 37 ° C. The amount of testosterone released was measured by spectrophotometry. The results of the in vitro release test are listed in Table 9.

Release of testosterone from hyaluronic acid / benzalkonium-chloride / gCD biocompatible in water and in different concentrations of NaCl solution at 37 ° C Time (hours) Testosterone released (%) in total dose In the water In 0.9% NaCl In 3% NaCl In 5% NaCl 1.5 2.0 9.8 17.0 18.0 3.0 4.6 12.0 18.0 19.0 6.0 5.5 17.6 18.0 21.2

The data suggest that the degree of release of the material captured from the biodegradable matrix according to the present invention is controlled by the actual ionic strength of the dissolution medium. When such a polymer / surfactant / cyclodextrin based biomaterial loaded with testosterone is applied to a biological system, release of the captured steroid is initiated by the cation concentration of the surrounding tissue. This degradation of the supramolecular matrix by the cations present follows the release of the testosterone trapped from the gCD complexed form to ensure sustained release of testosterone.

Example 21 : Prostaglandin E by two consecutive injections ₂ In situ formation of insoluble biomaterials loaded with

5 g of g-cyclodextrin and 1 g of hyaluronic acid are dissolved in 100 ml of sterile deionized water for injection. 2 ml of this thick solution is filled into an injection syringe.

Another solution is prepared by dissolving 1 mg of prostaglandin E ₂ in 10 ml of 30% Luviquat Mono CP surfactant. 0.5 ml of the prostaglandin solution is transferred to an injection syringe. After successive subcutaneous injections to the rat, the biocompatible material loaded with the drug is formed in situ, thereby ensuring sustained prostaglandin release.

Any type of composition described in Examples 1-15 can be applied by continuous injection to cause in situ formation of an insoluble matrix suitable for biomedical and other uses.

Example 22 Preparation of hyaluronic acid / surfactant / phospholipid / gamma-cyclodextrin polymer matrix

A solution of 100 ml volume was prepared by dissolving 5 g gamma-cyclodextrin and 1 g hyaluronic acid in deionized water. The solution represents a slightly cloudy viscous liquid with no solid particles.

5 ml of 5% benzalkonium-chloride aqueous solution was stirred at 40 ° C with 0.3 g of egg yolk-phosphatidylcholine to obtain a homogeneous emulsion. 10 grams of the hyaluronic acid / γ-cyclodextrin solution described above was reacted with 5 ml of phosphatidylcholine / benzalkonium-chloride emulsion at room temperature. After stirring for about 10 minutes, a weak yellow water-insoluble polymer matrix was obtained. The polymer was filtered off, washed with 5 ml of deionized water and dried in vacuo onto P ₂ O ₅ until constant.

Yield: 0.62 g (54%) of rubbery solid.

The composition of the polymeric material according to Example 22 contained about 20% hyaluronic acid, 40% γ-cyclodextrin, 25% phospholipid and 8% benzalkonium chloride.

Example 23 Preparation of Alginic Acid / Surfactant / Phospholipid / Gamma-cyclodextrin Polymer Matrix

5 mL of 5% benzalkonium-chloride aqueous solution was stirred at 40 ° C with 0.3 g of egg yolk-phosphatidylcholine to obtain a uniform emulsion. 10 grams of 1% alginic acid and 5% gamma-cyclodextrin containing solution were mixed with 5 ml of phosphatidyl-choline / benzalkonium-chloride emulsion at room temperature. After vigorous mixing for about 15 minutes, a slightly yellow polymer precipitate formed. The precipitate was filtered off and washed with 5 ml of water. 0.55 g of solid elastic rubber was obtained after drying to constant weight.

Example 24 : Surgical Wound Cover Sheet Made of Polymer Matrix According to the Present Invention

Polymeric biocompatible materials were prepared according to Example 1. The wet product was isolated by filtration and washed three times with 500 ml of deionized water. The washed wet product was wound in a layer about 1 mm thick on the wet glass surface and immersed in cold (about 5 ° C.) acetone. After soaking in acetone for about 30 minutes the product became a dehydrated white solid paper-like sheet. After this drying process, acetone was removed by drying in vacuo. The product may be rewet in sterile water, while it again becomes a visco-elastic polymer and may be applied as a wound covering sheet to speed up the wound healing process.

Example 25 : Antibiotic wound dressing / covering film composed from the polymer matrix according to the invention

The mucoadhesive film containing antibiotics contained 100 ml of 1% hyaluronic acid solution containing 5 g of gamma-cyclodextrin and 50 ml of 30% rubicuat mono containing 1 g of dissolved cyprofloxacin. Luviquat Mono) to react with CP solution. After mixing the two solutions, the white precipitate formed was separated by filtration. The white polymer matrix was washed with 50 ml of water and wound into a 1 mm thick layer. The wet layer was dried in vacuo until constant weight. Yield: 10 g of white elastic polymer sheet containing 7.8% of cyprofloxacin. Re-wetting the polymer sheet in sterile water after sterilization was found to provide a viscoelastic wet film useful for covering the wound skin surface or wound.

Example 26 : Conductive polymer matrix containing trapped iodine

The electrically conductive polymer fibers consist of 100 ml of 1% hyaluronic acid solution containing 5 g of gamma-cyclodextrin and 50 ml of 30% Luviquat Mono CP solution containing 1 g of dissolved elemental iodine. Prepared by reacting. The yellowish brown precipitate formed after mixing the two solutions was separated by filtration. The polymer matrix was washed with 50 ml of water and stretched to about 1 or 2 mm diameter fibers. The wet fibers were dried by immersion in cold (10 ° C.) acetone and then vacuum dried. Yield: Brown elastic polymer fiber sheet containing about 8% by weight of elemental iodine. The polymer fibers were found to be electrically conductive. The conductivity was found to be different in the other direction, and the axial conductivity in the stretching direction was much higher than that in the transverse direction. The higher order structure of these supramolecular assemblies enabled electrical conductivity even in polymer matrices free of any iodine.

Example 27 : Allantoin-containing wound healing cover sheet composed from the polymer matrix according to the present invention

The mucoadhesive film containing allantoin contains 100 ml of aqueous solution containing 1 g of hyaluronic acid and 5 g of α-cyclodextrin and 25 ml of 30% Rubiquat mono containing 2 g of dissolved allantoin (Luviquat). Mono) to react with a CP solution. After reacting the two solutions, a white precipitate formed. The polymer precipitate was separated by filtration and washed with 25 ml of water. The wet product was wound into a uniform layer 1 mm thick. The wet layer was dried in vacuo until constant weight. Yield: 7.7 g of white polymer sheet. After sterilization, the polymer sheet was rewet in sterile water to provide a viscoelastic film useful for wound dressings to aid in wound healing.

Example 28 : A surgical surgical seal from the polymer matrix according to the invention

The solution containing hyaluronic acid and gamma-cyclodextrin was reacted with a Luviquat Mono CP solution containing 2% glycerin according to the scheme described in Example 1. After the reaction was completed, the resulting wet polymer matrix was washed with deionized water, then the wet polymer was stretched and wound into a yarn of about 0.2 mm thick to make a yarn. The yarn was immediately immersed in acetone and dehydrated to give a dry elastic yarn.

The resulting thread can be used for surgical closure of the wound. These biodegradable seals may also be used as implants after loading the appropriate pharmaceutically active ingredient.

Example 29 In vitro Enzymatic Degradation of Polymer Matrix Prepared According to the Present Invention

Degradation of hyaluronic acid incorporated into the polymer matrix according to the invention is carried out in a pH 6.5 phosphate buffer by hyaluronidase enzyme after a 42-hour incubation time using a control uncaptured hyaluronic acid substrate for comparison. After stopping the enzyme activity, the reaction mixture was evaluated by capillary zone electrophoresis. Electropherograms show that hyaluronic acid was actually released from the polymer matrix and degraded by the hyaluronidase enzyme. The hyaluronic acid / Luviquat Mono CP / gamma-cyclodextrin matrix according to Example 1 was found to be capable of degradation at a slower reaction rate by enzymes. The distribution of degradation products was similar to that of the control hyaluronic acid digested by the hyaluronidase enzyme.

Example 30 : Fate of Implanted Polymer Matrix According to the Invention in Rats

Two animal tests were performed. In the first orienting experiment, three male Wistar rats (average weight 400 g each) were treated with a very high dose (1 g, 2 g and 4 g) of the polymer matrix according to Example 1.

The implant's location in the animals was re-opened after 2 and 3 weeks, respectively. Peripheral tissue of the implanted polymer material was evaluated visually and microscopically. In both 1 g and 4 g implants, the tissue around the implant was shown to be inflamed, and a significant increase in white blood cell counts suggested an inflammatory condition in the treated animals. However, the inflammation presented was mild and none of the treated animals showed systemic toxicity, despite extremely high doses, and each survived well. Rats receiving 2 g implants 3 months after transplantation were still in perfect condition.

HPLC analysis of tissue / wash samples taken from the site after 2 weeks showed no traces of hyaluronic acid or gamma-cyclodextrin and surfactants could be detected. This indirectly demonstrates that the polymer matrix according to Example 1 is completely removed from subcutaneous transplantation within a few weeks even when administered at high doses (4 g per 400 g rat), thus it appears to be biodegradable.

Example 31 : Preparation of a Binary Biocompatible Material According to the Invention, Comprising Carbopol ™ 9880 NF as Anionic Polymer and Luviquat Mono CP as Surfactant

25 g of gamma-cyclodextrin (gCD) and 5 g of Carbopol® 9880 NF are dissolved in 470 g of deionized water at room temperature (25 ° C.) to give a slightly cloudy solution. To this solution was stirred 17 ml of Luviquat Mono CP solution containing 30% (5.1 g) of cetyl-dimethyl- (2-hydroxy-ethyl) -ammonium dihydrogen-phosphate with gentle stirring. Add. Immediately, a white precipitate is formed that forms an elastomer-like object within an additional 15 minutes. The isolated wet polymer object is washed three times with 100 ml of deionized water and dried.

Yield: 9.8 g of white glassy polymeric material

Composition of the precipitate prepared according to example 31

Furtherance (%) Carbopol® 9880 NF Gamma-CD Luviquat® Mono CP About 50 0 Approximately 46

Polymeric matrices of this type have an undetectable amount of gamma-CD content and are found to be rather rigid semisolids that do not have viscoelastic properties.

The DSC curve of the material recorded in N ₂ atmosphere shows three stages of endothermic heat flow with mass loss. The mass loss is 17.7% in the range up to 250 ° C, and 25.6% at up to 300 ° C.

Example 32 Preparation of a two-component biocompatible material according to the invention comprising Carbopol® 9880 NF as anionic polymer and benzalkonium chloride as surfactant

Solution 1 : 5 g of gamma-CD and 1 g of Carbopol® 9880 NF are dissolved in 94 g of deionized water to produce a slightly cloudy solution.

Solution 2 : 8 ml of 50 wt% Benzalkonium Chloride Solution (BAC)

Process : Solution 2 is added to stirred Solution 1 at 25 ° C. Mixing the two solutions forms a white precipitate. No object is formed during the reaction time of about 30 minutes, only a floppy white precipitate is obtained. The reaction mixture is then placed in a refrigerator (5 ° C.) for 12 hours to form a thick gel. After diluting this gel with 4000 mL of deionized water, a white insoluble polymer material precipitates. The precipitate is filtered off and washed five times with 200 ml of water. 5.1 g of white elastic rubber-like material are obtained. The mechanical properties of this material are completely different from those similarly prepared on the basis of hyaluronic acid. Polymeric objects exhibit great elasticity and resistance to external forces. It retains its shape against any physical interference due to its significant elastic properties. This material does not include gamma-cyclodextrin as shown in the table below.

Composition of the precipitate prepared according to example 32

Furtherance (%) Carbopol® 9880 NF Gamma-CD BAC About 50 0 Approximately 46

Example 33 : Preparation of a Bicomponent Biocompatible Material According to the Invention Containing Pioneer® NP 37N Sodium Carbomer as Anionic Polymer and Luviquat Mono CP as Surfactant

25 g of gamma-cyclodextrin (gCD) and 2.5 g of Pioneer® NP 37N sodium carbomer are dissolved in 470 g of deionized water at room temperature (25 ° C.) to give a slightly cloudy solution. To this solution was slowly stirred a 9 ml Luviquat Mono CP solution containing 30% (2.7 g) cetyl-dimethyl- (2-hydroxy-ethyl) -ammonium dihydrogen-phosphate Add. Immediately, a white precipitate is formed that forms an elastomer-like object within an additional 15 minutes. The isolated wet polymer object is washed three times with 80 ml of deionized water and dried.

Yield: 3.3 g white glassy polymeric material

Composition of the precipitate prepared according to example 33

Furtherance (%) Carbopol® 9880 NF Gamma-CD Luviquat® Mono CP About 50 0 About 50

Example 34 : Resistance of Palmitoyl-L-Carnitine / Haluronic Acid / Gamma-CD Polymer Matrix in Mice After Subcutaneous Transplantation

Palmitoyl-L-carnitine / hyaluronic acid / gamma-CD polymer matrix is prepared under sterile conditions and includes 53% palmitoyl-L-carnitine, 40% hyaluronic acid and 2% gamma-cyclodextrin.

The test animals are NMRI female mice with an average weight of 25 grams. Animals receive 40 mg of this matrix on the back of the neck as an implant by hydrophobic intervention. There are also two types of "positive control" groups: one group of animals is exposed to "pseudo-surgery" without implants, and the other group contains 40 mg of poly-L. Provides lactic acid polymer implants. After placement and fixation of the implant, the general condition and white blood cell count of the test animal are recorded continuously. At different time intervals, the graft site is re-opened to investigate the ultimate local irritation and / or inflammation caused by the graft. In addition, biodegradation of the polymer matrix is assessed by visual inspection and by light microscopy, and the surrounding tissue of the test animal around the implant is histologically evaluated.

Results : The results of total leukocyte counts of treated and control animals as a function of time after implantation were summarized in the following table.

Leukocyte counts in control and treated mice after 40 mg of poly-L-lactic acid and palmitoyl-L-carnitine / hyaluronic acid / gamma-CD implants

Total white blood cell count (× 10 ⁶ ) 1 day 2 days 4 days 8th 21st contrast 6.3 4.6 6.2 4.5 6.4 Singer 8.1 5.5 6.6 4.6 3.9 PLA ^* 7.4 5.7 6.2 3.8 4.4 PLC / HA / gCD ^** 6.2 4.4 6.5 3.9 3.2 * Poly-L-lactic acid control implant ** palmitoyl-L-carnitine / hyaluronic acid / gamma-cyclodextrin matrix

The above data suggest that substantially no detectable inflammation is caused by the polymer matrix according to the present invention. There is no significant difference between control and treated animals in terms of white blood cell counts after surgical intervention.

After re-opening the graft, no observable local irritation or inflammation appeared visually. Tissue samples taken immediately close to the implant showed no histological signs of inflammation after histological / microscopic evaluation. These observations, along with hematological data, indicate that subcutaneous diets of palmitoyl-L-carnitine / hyaluronic acid / gamma-CD base polymer matrix of 1.6 g per kilogram of body weight (in the human case this is about 110 g / human). It does not cause any irritation or any toxicity problems during the observation period. In addition, the average removal time of the polymer matrix implanted in mice was found to range from 3 weeks to 1 month.

Claims (28)

At least an anionic polymer component and an amphiphilic ammonium-type component which are themselves soluble in water, in an amount effective to form a precipitate, 1. contacting the anionic polymer component and the cyclodextrin component in an aqueous medium, and 2. Adding amphiphilic ammonium-type component to the mixture obtained in step 1 A precipitate that can be obtained by a method comprising a. The precipitate of claim 1 further comprising the cyclodextrin component. The precipitate according to claim 1 or 2, further comprising at least one additional component different from the cyclodextrin component added in the process of step 1 and / or step 2 of the method. 4. The precipitate of claim 3 wherein said at least one other ingredient is selected from pharmaceutically active ingredients, pesticides, pesticides, colorants, diagnostic agents, enzymes and foods. The anionic polymer component according to any one of claims 1 to 4, wherein the anionic polymer component is hyaluronic acid, carboxymethyl cellulose, carboxymethyl starch, alginic acid, polyacrylic acid-type polymer component, pectin, xanthan rubber, tragacantha rubber, A precipitate that is a member of a group consisting of a water soluble salt of one of the components, and a mixture of two or more of said members. The precipitate according to any one of claims 1 to 5, wherein the amphiphilic ammonium-type component comprises a cationic surfactant. The amphiphilic onium type component according to any one of claims 1 to 6, wherein the amphiphilic onium type component is benzalkonium chloride, benzoxonium chloride, cetyl-pyridinium chloride, cetyltrimethylammonium bromide, cetyldimethyl (2-hydroxyethyl). Ammonium Dihydrogen Phosphate (Luviquat Mono CP), Cochamidopropyl-N, N, N-trimethyl-glycine, Acyl Carnitine, in particular Palmitoyl Carnitine, Sodium Cosyl Glutamate and one of these groups A precipitate selected from the group consisting of the above mixtures. The precipitate according to any one of claims 1 to 7, wherein the amphiphilic onium type component comprises a cationic phospholipid. 9. The precipitate of claim 8 wherein the cationic phospholipid is selected from lysophosphatidyl-choline compounds, phosphatidyl choline compounds, sphingomyelin, sphingosine derivatives and mixtures thereof. The precipitate according to any one of claims 1 to 9, wherein the cyclodextrin component is selected from alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and mixtures thereof. The precipitate of claim 4, wherein the at least one additional ingredient comprises a pharmaceutically active ingredient. The method of claim 11, wherein the pharmaceutically active ingredient is a steroid, prostanoid, nitric oxide prodrug, antihistamine, antibiotic, cytostatic, antiviral, peptide hormone, local anesthetic, antiglaucoma, anti-inflammatory, antihypertensive, anti Precipitates selected from the group consisting of angiogenic agents and suitable combinations thereof. Anionic polymer component, cyclodextrin component, and additional components contained in the precipitate and soluble in water are dissolved in an aqueous medium to form a first composition; The amphiphilic component and additional components contained in the precipitate and insoluble in water are blended with a suitable liquid carrier, preferably an aqueous medium to form a second composition; Blending the first and second compositions to form a precipitate A process for preparing a precipitate according to any of the preceding claims. The method of claim 13, wherein the precipitate is prepared in the desired form. The method of claim 13 comprising treating a non-liquid carrier to coat it with the first composition, and subsequently treating the treated carrier with the second composition to form a coating of precipitate on the carrier. . A pharmaceutical composition comprising the precipitate according to claim 11. The pharmaceutical composition of claim 16, which is a depot preparation. Medical device comprising a precipitate according to claim 11. A medical implant or insert according to claim 18. Two or more partial compositions, each comprising one or more of the components of the pharmaceutical composition, whereby the components intended to form a precipitate are present in the composition for continuous or simultaneous administration in an amount effective to form the precipitate, the composition 18. A kit for administering a pharmaceutical composition according to claim 16 or 17 by forming a composition at the location where it is administered by administering portions of the same or preferably continuously to the subject. The method of claim 20, A first composition comprising an anionic polymer component, a cyclodextrin component, and an additional component contained within the precipitate and soluble in water dissolved in an aqueous medium; And A second composition comprising an amphiphilic component and a component contained in the precipitate and insoluble in water, blended with a suitable liquid carrier, preferably an aqueous medium Kit comprising a. 22. The kit of claim 20 or 21, adapted to administer the pharmaceutical composition subcutaneously or intramuscularly. 22. The kit of claim 20 or 21, wherein the kit is adapted to be administered by spraying the pharmaceutical composition onto a wound, skin or other solid surface. A method of administering a pharmaceutically active compound to a subject in need thereof, comprising administering a pharmaceutical composition according to claim 16 or 17 comprising a pharmaceutically active compound. Two or more partial compositions, each comprising one or more of the components of the pharmaceutical composition, by simultaneously or preferably continuously administering to form a pharmaceutical composition at the site and location of the administration (where the components to form a precipitate are 18. A method of administering a pharmaceutical composition according to claim 16 or 17 to a subject, which is present in the partial composition in an amount effective to form a precipitate when in contact with each other. The method of claim 25, A first composition comprising an anionic polymer component, a cyclodextrin component, and additional components contained in the precipitate and soluble in water dissolved in an aqueous medium; And A second composition comprising an amphiphilic component and a component contained in the precipitate and insoluble in water, blended with a suitable liquid carrier, preferably an aqueous medium Administering simultaneously or preferably continuously. 27. The method of claim 25 or 26, wherein the partial composition is injected subcutaneously or intramuscularly into the subject. 27. The method according to claim 25 or 26, wherein the partial composition is preferably sprayed onto the wound, skin or other solid surface.